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tables. The vast majority of included studies were carried out in Europe, being 4 of 
them in United Kingdom. Ten studies considered lifetime horizon and two studies 
five- and one-year horizon. Diabetics and non-diabetics patients were taken into 
account in almost all models. Changes in body mass index (BMI) promoted by the 
pharmacotherapy were correlated to the risk of experiencing coronary heart dis-
eases, stroke or death in ten studies. Furthermore, two models took into account 
natural BMI increasing due to population ages. Besides BMI, some models were 
sensitive to changes in total cholesterol, HDL, systolic blood pressure and gly-
cated hemoglobin for diabetics. Finally, equations derived from Framingham Heart 
Study (FHS) were the most common ones used to populate models and competing 
risks events were not discussed in most of studies. ConClusions: Health-state 
transition modelling seems to be the most appropriate methodology to assess 
obesity’s pharmacotherapy. Future studies should explore other co-morbidities 
and competing risks events. Furthermore, equations used to populate models 
must be coherent to target population characteristics.
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objeCtives: Rare diseases (RD) are an important bench test case for healthcare 
services organization. This for both moral and ethical aspects which implies know-
ing how to cope with the needs of a vulnerable sector of population. At the same 
time RD its a challenge for healthcare service organizations, which are called to 
respond to particularly emphatic individual requirements. Methods: The study 
has been developed on administrative database of the Regional health care system 
of Lombardia Region, containing all the services provided to resident population 
and the related costs (or tariffs recognized by the the Regional System). The analy-
sis includes all the citizen benefiting of an exemption from copayments due to 
a rare diseases condition. The RHS (regional health care system) perspective has 
been adopted. Results: The analysis covered 44,548 subjects with copayment 
exemption due to RD. The prevalence (2012) was equal to 0.46% of the resident 
population, with a significant gender difference: 0.39% for males and 0.53 % for 
females. The average annual expenditure per rare diseased patient amounts to € 
5,003.1, a value approximately comparable to the average one for patients with at 
least two chronic conditions (€ 4,500.2). In terms of gender the figure for women 
(€ 3,539.3) is significantly lower than that for males (€ 6,856.6). The total impact 
on RHS is € 222.9 M, equal to 1.21% of regional spending. Patients with ultra rare 
disease are characterized by costs (€ 6,953.6 pro capita) significantly above the aver-
age. ConClusions: the research give some original insight on the prevalence and 
economic impact of RD patients in a large population. It permits to appreciate the 
potential organizational and economic impact od RD patients, especially of those 
with an ultra-rare condition, as well as financial risk for the local health care units 
due to prevalence concentration.
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objeCtives: In Germany, orphan drugs are assessed based on their EMA orphan 
designation and expected annual budget impact. Per German law, the additional 
benefit criteria is automatically met if the product is a qualified orphan drug. 
Products with expected annual budget impact of ≤ € 50 million annually qual-
ify and therefore are only required to submit an abbreviated dossier. Products 
with expected budget impact > € 50 million must submit a full dossier and are 
assessed on ability to demonstrate added benefit. This examines how orphan 
drugs have been reviewed post-AMNOG in Germany, including their resulting price 
rebates. Methods: GfK reviewed all EMA orphan-designated market authoriza-
tions since 2011 and cross-referenced products with the dossier submitted. GfK 
then reviewed G-BA resolutions to determine which target populations, population 
sizes, and comparators had been evaluated to determine final benefit assess-
ments. Subsequently, individual product prices were researched to determine the 
corresponding negotiated AMNOG rebates. Results: From 2011 to 2015 40 EMA 
orphan designated products received marketing authorization - only 16 of these 
products were assessed as orphan drugs in Germany. Of these, 10 were indicated 
for oncology (62.5%) and 6 (37.5%) for non-oncology indications. In their largest 
sub-populations, 8 (50%) products achieved ‘minor additional benefit’, 6 (37.5%) 
received ‘unquantifiable additional benefit,’ while only 2 (12.5%) achieved ‘con-
siderable additional benefit.’ Across 11 products, the average total rebate (AMNOG 
negotiated rebate + mandatory rebate) was 32%, however, varied highly and ranged 
between 15% and 50%. Our analysis also looked across other factors (e.g., rebate as 
it relates to benefit rating). ConClusions: Due to their expected budget impact, 
most EMA orphan-designated drugs did not qualify for the abbreviated dossier. 
However, neither a full or abbreviated submission could concretely be linked to 
a higher benefit assignment; high benefit scores do not necessarily guarantee 
smaller rebates off the free price.
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objeCtives: Informal caregiver burden is not formally or routinely considered in 
health technology assessment (HTAs). However, the burden of many diseases on 
informal caregivers’ quality of life has been recognized, including hematologi-
cal cancers. This study aimed to understand the role of informal caregiver burden 
in HTA in France, Germany, and the US, using the example of multiple myeloma 
Furthermore, the highest approved ICER value of all NICE appraised rare disease 
submissions was noted at £47,200/QALY, while 7 technologies with ICERs above 
£50,000/QALY were rejected. ConClusions: ICER thresholds in the UK continue 
to be barriers to access therapies for rare diseases, although recent policy revisions 
may lead to changes in access in this market.
PSY126
cHAllEngES for ASSESSing tHE Economic vAlUE of orPHAn drUgS - A 
litErAtUrE rEviEw of cUrrEnt And AltErnAtivE APProAcHES
Cote S1, Gaudig M2, Nielsen SK3, Shields GE4, Britton JA4
1Janssen-Cilag, Bucks, UK, 2Janssen Health Economics & Market Access EMEA, Neuss, Germany, 
3BresMed, Panjim, India, 4BresMed, Sheffield, UK
objeCtives: Assessing the economic value (EV) of orphan drugs (ODs) within the 
existing health technology assessment (HTA) framework is challenging. We therefore 
decided to evaluate current and alternative HTA approaches for ODs. Methods: 
Published studies from 2000 to July 2014 focusing on methods for assessing the 
EV of ODs were identified via MEDLINE. A targeted search for recent HTA submis-
sions was also performed, covering five ODs we selected as most relevant (bosu-
tinib, brentuximab vedotin, everolimus, pomalidomide and ruxolitinib) across six 
European countries (France, Germany, Ireland, the Netherlands, Sweden and the 
UK). Results: Eleven published papers were identified. All papers concluded that 
ODs are not suited to standard economic evaluations and the current HTA frame-
work. The primary reasons were inadequate evidence of efficacy due to low patient 
numbers, lack of important outcome measures such as quality of life, no long-term 
outcomes data, and no information on the systemic impact of the disease beyond 
the health impact, i.e. financial, emotional and social. The inherent uncertainty 
regarding short- and long-term health gains combined with high acquisition costs 
leads to incremental cost-effectiveness ratios well beyond existing HTA thresh-
olds. We identified alternative methods such as including societal value, emphasis-
ing burden of illness and using variable thresholds, weighted outcome measures, 
surrogate markers and alternative statistical approaches like Bayesian methods. 
However, none of these have been implemented in existing HTAs. We confirmed 
this in our review of HTAs, which also showed inconsistency in decisions taken by 
HTA bodies. ConClusions: Assessing EV of ODs remains a challenge. Despite being 
discussed in the literature, no innovative methods have been used in recent HTA 
submissions. HTA bodies, companies developing ODs, patients and society must 
engage in further discussions on how to assess value. Until then, considerable risk 
remains that access to ODs is unequal compared to non-ODs and across countries.
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objeCtives: To understand European Union (EU) and Australian payer perceptions 
and challenges in the evaluation of emerging health technologies with orphan and 
ultra-orphan designations. Methods: In-depth, qualitative, one-on-one inter-
views were conducted with payer decision makers representing Australia and the 
EU-5: France, Germany, Italy, Spain, and the United Kingdom from the RTI Health 
Solutions Payer Advisory Panel. Results: Payers identify the biggest challenges as 
lack of clinical and comparative efficacy data and pressures from advocacy groups, 
patients, and prescribers to fund the ever-increasing numbers of orphan and ultra-
orphan technologies, which are often very expensive and have limited clinical evi-
dence. Understanding the disease and its burden and unmet needs was consistently 
highlighted. All payers estimated that spending for orphan and ultra-orphan tech-
nologies will increase significantly in the next 5 years, leading to concerns over 
future funding and budgets. Clawbacks in France will be common; employment 
of the rule of rescue in Australia and pricing pressures in Italy, Spain, and the UK 
are to be expected. Payers wanted to see better-defined patient populations and 
unmet needs accompanied by well-defined treatment courses (e.g., when to stop 
treatment). Benefits of new technologies will not be captured in traditional health 
economic analyses, thus increasing uncertainty. Bridging the clinical evidence with 
other robust data will be critical. The cost to the systems was highlighted as a con-
sistent concern. More emphasis on showing the value, affordability, comparative 
effectiveness, and cost offsets is critical. ConClusions: Payers are seeking more 
value-based information to better inform decision making in the evaluation of new 
orphan and ultra-orphan technologies. The challenge lies with the value of the new 
technology and who is judging that value. Rising costs of orphan and ultra-orphan 
technologies will have more impact on market access in the future, with increasing 
resistance to high prices.
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objeCtives: To describe and discuss existing pharmacoeconomic models assess-
ing obese or overweight patients being treated with anti-obesity drugs Methods: 
Medline and EMBASE were searched for cost-effectiveness or cost-utility-analy-
sis reporting in full decision modelling used. It was eligible for assessment only 
studies considering Quality Adjusted-Life Years or Life-Year Gained as the final 
outcome and assessing pharmacotherapy as intervention. Data regarding popula-
tion, study’s perspective, time-horizon and methodology used were described. It 
was discussed the sensitivity of the model for obesity’s co-morbidities such as 
cardiovacular diseases and type 2 diabetes mellitus and their reliability with clini-
cal practice. In addition, it was explored the risk equations used to populate the 
model. Results: From 51 studies assessed in full, twelve of them complied with 
our inclusion criteria being that were identified twelve different models. The most 
common methodology used was health-state transition modelling followed by life-
